Transplantation of pancreatic islets of Langerhans as a therapeutic approach for treatment of type I diabetes offers an alternative to subcutaneous insulin injections. Normalization of blood glucose levels by transplanted islets may prevent the development of diabetes-related complications. Problems related to rejection, recur rence of autoimmunity, and local inflammation upon transplantation of islets into the liver need to be solved before the implementation of islet cell transplantation can be viewed as a justifiable procedure in a large cohort of patients. Islet cell isolation has been quite successful in small animals, but the translation of this approach to nonhuman primates has been less rewarding. One of the main problems encountered in nonhu man primate models is the difficulty of isolating an adequate number of functional islets for transplantation. The aim of the present study was to develop a method for isolating a sufficient number of viable islets from nonhuman primates to allow for reversal of diabetes. By implementing minor modifications in the automated method for human islet isolation we were able to obtain viable, functional islets that responded normally to glucose stimulation in vitro. These islets were also able to reverse diabetes in immunocompromised nude mice, rendered diabetic by streptozotocin. This method of islet cell isolation has enabled us to proceed with protocols of allogeneic islet cell transplantation in preclinical, nonhuman primate models.
INTRODUCTION
Transplantation of pancreatic islets of Langerhans represents a potential cure for type I diabetes. Normal ization of blood glucose levels by the transplanted islets may prevent the development of diabetes-related com plications (15) . In recent years, remarkable progress has been made in the field of islet cell transplantation. Be fore islet cell transplantation can be applied to a large cohort of patients, new strategies aimed at the induction of donor-specific tolerance, requiring only transient im munosuppression or no conventional immunosuppres sion at all, need to be developed (8, 10) .
Nonhuman primates are highly relevant preclinical models due to their close phylogenetic relationship to humans. Islet cell transplantation has been quite success ful in small rodent models, but the translation of this approach to nonhuman primates has been less rewarding (12) . One of the main problems encountered in nonhu man primate models is the difficulty of isolating an ade quate number of functional islets for transplantation.
The aim of the present study was to develop a method for isolating a sufficient number of viable islets from nonhuman primates to allow for reversal of diabe tes in preclinical, nonhuman primate models (5).
MATERIALS AND METHODS

Animals
Male adult rhesus (Macaca mulatta; n = 15) and cynomolgus (Macaca fasicularis; n = 4) monkeys ranging in age over 4 years and weighing over 5 kg were ob tained from COVANCE (Alice, TX) or through local sources (Charles River, Homestead, FL) to serve as pan creas donors. Donor pancreatectomy was performed un der general anesthesia (isoflurane) through a midline incision. Briefly, the splenocolic and splenorenal liga ments were divided and the tail of the pancreas was mo bilized together with the spleen. The common bile duct, the main, and occasionally the accessory pancreatic ducts were identified and ligated. The animal was exsan guinated through a catheter placed in the abdominal aorta. The head of the pancreas was excised from the second portion of the duodenum by sharp dissection. Similarly, the rest of the pancreas was excised from the 410 RANUNCOLI ET AL. surrounding tissues. The pancreas was taken out, en block, with the spleen.
For the in vivo functional assessment of islets, islets were transplanted into athymic, adult nude mice, weigh ing between 18 and 20 g, which had been made diabetic with streptozotocin (Charles River, Wilmington, MA).
All experiments were conducted according to the standards set forth in the Guide for the Care and Use of Laboratory Animals.
Nonhuman Primate Islet Isolation
Islet cell isolation and purification were performed using minor modifications of the automated method for human islet isolation described by Ricordi (11) . Top layer  51135  19 ± 12  8±9  6 + 7  3 + 2  Bottom layer  6+13  2+6  2±5  1±3  0±1  0±l Top layer: interface between the 1.096 and 1.037 gradients. Bottom layer: interface between the 1.096 and the 1.108 gradients.
temperature was brought to 37°C, and the chamber was gently shaken over a period of approximately 13 min.
The digestion process was stopped by addition of 50 ml of fetal bovine serum (FBS) to the beaker, and re leased tissue was collected into 4°C RPMI-1640 supple mented with 10% FBS. After centrifugation at 250 x g in 250-ml tubes, the pellets were collected in Eurocollins solution and held on ice. After all the pellets were com bined and centrifuged, the resulting pellet was 3.8 + 1.6 ml. The processed tissue was purified using a three-layer discontinuous gradient. Each gradient consisted of Ficoll powder (Cellgro, Herndon, VA) in Eurocollins solution at specific densities of 1.108, 1.096, and 1.037 g/ml. The pellet was resuspended in 225 ml of the 1.108 gradient and loaded into a Cobe bag, followed by addition of 125 ml 1.096, 100 ml 1.037, and 50 ml HBSS. A Cobe blood cell processor (Cobe, Lakewood, CO) was used for cen trifugation of the gradients (2000 rpm for 3 min) and purification of islets from the digest. Islets were identi fied and quantified by dithizone staining (Sigma, St. Louis, MO) of aliquots of the final preparation (6) . The number of islets in each of the size ranges 50-100, 100-150, 150-200, 200-250, 250-300, 300-350, and 350-400 pm was counted, and the total number of islets was normalized to islets of 150 pm diameter (islet equiva lents, IEQ). 
In Vitro Assessment
Static incubation of islets at different glucose concen trations was performed to evaluate islet response to glu cose. Briefly, triplicates of 50 IEQ were incubated at 37°C in Krebs-Ringer bicarbonate buffer containing 1.67 mmol/l glucose for 1 h, followed by a second 1-h incubation with 16.7 mmol/l glucose (1, 4) . The amount of insulin released into the supernatants was assayed us ing a radioimmunoassay.
In Vivo Assessment
Using a previously described technique ( 
Statistical Analysis
Results are expressed as means ± SD. Analysis of data was performed with Microsoft Excel. 
RESULTS
Analysis of Islet Yield
The results of islet isolation are shown in Table 1 . Cynomolgus pancreata were smaller than rhesus pan creata (6.9±1.9 g, n = 4, vs. 15.4 ±4.6 g, n=15), but the efficiency (islets/gram) was higher for cynomolgus than rhesus (11,367 ± 1.7 vs. 7919 ± 1658 islets/g). Nev ertheless, from a single pancreas, we obtained sufficient numbers of islets for utilization in nonhuman primate models of islet allotransplantation (5) .
The islet yield was 75,799 ± 7303 (51,410 ± 16,127 IEQs) from cynomolgus and 90,847 ± 17,937 (79,139 ± 17,869 IEQs) in rhesus pancreata (Table 1) .
A representable example of dithizone-stained islets is shown in Figure 1 , and the size distribution for rhesus and cynomolgus islets is given in Table 2 .
In Vitro Functional Assessment of Purified Islets
At low glucose concentration (1.67 mmol/l), insulin release was 11.9 ± 1.4 uU/ml/h/islet for monkey islets (n = 9, n = 7 for rhesus; n -2 for cynomolgus). At high glucose concentration (16.7 mmol/l), insulin release in creased to 42.2 + 3.6 uU/ml/h/islet (Fig. 2) . A prompt decrease in insulin release for both species (16.1 ± 1.2) was observed when islets were returned to low glucose concentration.
In Vivo Functional Assessment of Purified Islets
After transplantation, all of the diabetic mice became normoglycemic within 4 days, irrespective of the islet source (rhesus or cynomolgus). Maintenance of normo glycemia was achieved throughout the follow-up period.
Thirty-six days after transplantation, nephrectomy was performed, and the transplanted animals promptly re turned to a hyperglycemic state ( Fig. 3) .
Immunoistochemical Study of Engrafted Islets
Histological analysis of the excised kidneys revealed the presence of well-granulated primate islets under the kidney capsule of immunodeficient rodents. Alkaline phosphatase based a-insulin immunostaining of the explanted islets is shown in Figure 4 . Islets appeared well granulated, with strong reactivity for insulin.
DISCUSSION
In this study we have described a procedure to obtain viable and functional nonhuman primate islets via minor modification of the automated method for human islet isolation. The enzyme concentration was lower as com pared to human islet isolation (0.47 vs. 1.4 mg/ml), the volume of the digestion chamber was 250 vs. 500 ml for the human islet procedures and the time of digestion was 13 vs. 23-33 min. We evaluated the islet preparations with three methods: 1) dithizone staining to quantitate IEQ; 2) in vitro, glucose-stimulated insulin release; and 3) ability to reverse hyperglycemia after transplantation under the kidney capsule of diabetic nude mice.
Islets isolated by this method had a normal response to in vitro glucose stimulation, including a return to basal secretion after the glucose stimulus was discon tinued. These islets were able to reverse diabetes in im munocompromised nude mice rendered diabetic by streptozotocin injection.
Many groups, as well as ours, have described nonhu man primate pancreatic islet isolation in the past (7, 9, 12, 13) . To the best of our knowledge, this is the first report demonstrating a method for consistent isola tion of an adequate number of viable and functional is lets from the pancreata of cynomolgus and rhesus mon keys to reverse diabetes in pancreatectomized monkeys.
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